ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MYGN
ACHV (39) NNNN (35) TKNO (42) QDEL (21) ⌘ Pro Terminal →

Myriad Genetics Inc. (MYGN) — RQD Stock Rating Cockpit

$5.85 -7.87% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.76

Myriad Genetics Inc. (MYGN) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $607.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MYGN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MYGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Myriad Genetics Inc. (NASDAQ: MYGN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $5.85 (-7.87% 1D, market cap $607.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MYGN ranks #306 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MYGN compare to ACHV and NNNN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), MYGN carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 69.9%, and ROIC of -35.0%. By comparison, ACHV (Achieve Life Sciences Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $702.8M) and NNNN (Anbio Biotechnology (Class A)) posts a D- grade (35/100 RQD, P/E 83.6x, ROIC 17.0%, cap $483.5M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MYGN?
▼

Per MYGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899923), Myriad Genetics Inc. generated $824.5M in revenue (-1.6% YoY), -$366.0M in net income, and $1.8M in free cash flow against $706.6M in total assets and $119.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.76 (-1.61%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D
Cash (8)Whales (14)SEC (8)Macro (12)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$9 Bull$6 Base$4 Bear
📬 FREE MYGN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MYGN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY MYGN SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)

FRED Regime × Technicals: 55% of 52W Range • RSI-14 at 67.9 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$4.08+35.8% Next Q
Q2 (-2Q)
42
Grade D$5.54+13.5% Next Q
Q3 (-1Q)
44
Grade D$6.29-7% Next Q
Current
47
Grade D$5.85-5.9% Hist 90D α
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MYGN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MYGN currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.35) and Max Pain ($6.14) forces dealer call-delta covering toward $8.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MYGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MYGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
67.930 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
6 / 99-Pt Accounting
52-WEEK LASER RANGE55% OF RANGE
L: $3$5.85H: $8
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 19 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on MYGN

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 69.9% gross margin and 0.28% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 0.20 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (52)

19/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like MYGN
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MYGN)

  • ✓Walkthrough of MYGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MYGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.42%📐 HORIZONTAL RANGE
2026-11-03O $6.67H $6.67L $5.85C $5.85VOL 1.50M
RES: $6.78SUP: $1.73SMA50: $4.35SMA200: $4.61
$7.05$5.88$4.71$3.55$2.38RES $6.78SUP $1.73$5.852026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MYGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MYGN Butterfly Map → + Track MYGN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -1.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MYGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MYGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MYGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MYGN)

Health Care Rank #306 of 1015 ⚔️ ACHV vs MYGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MYGN vs. ACHV, NNNN, TKNO, QDEL)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Myriad Genetics Inc. (MYGN) ranks #306 by composite RQD confidence (47/100, grade D) and #413 by equity capitalization ($607.4M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. MYGN currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MYGN ACTIVE
Myriad Genetics Inc.
D 47/100 — 69.9% -35.0% -7.87% $607.4M Benchmark Subject
ACHV
Achieve Life Sciences Inc.
D- 39/100 — — -35.0% -3.22% $702.8M /achv-vs-mygn →
NNNN
Anbio Biotechnology (Class A)
D- 35/100 83.6x 87.2% 17.0% +4.46% $483.5M /nnnn-vs-mygn →
TKNO
Alpha Teknova Inc.
D- 42/100 — 33.2% -21.3% -4.75% $454.1M /tkno-vs-mygn →
QDEL
QuidelOrtho Corporation
E 21/100 — — -35.0% +5.89% $908.6M /qdel-vs-mygn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000899923 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Myriad Genetics Inc. (MYGN) reported GAAP revenue of $824.5M (-1.6% vs. FY2024 revenue of $837.6M , and +9.5% cumulative change since FY2023) , GAAP net income of -$366.0M, operating cash flow of $1.8M, and free cash flow of $1.8M (+120.7% YoY). On the balance sheet, MYGN closed FY2025 with $706.6M in total assets against $119.9M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $824.5M -$366.0M $1.8M $1.8M $706.6M $119.9M
FY2024 (FY) 2024-12-31 $837.6M -$127.0M -$8.7M -$8.7M $1.03B $39.6M
FY2023 (FY) 2023-12-31 $753.2M -$263.0M -$110.9M -$110.9M — —

3. MYGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MYGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Myriad Genetics Inc. (NASDAQ: MYGN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $5.85 (-7.87% 1D, market cap $607.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MYGN ranks #306 in composite RQD confidence.

How does MYGN compare to ACHV and NNNN in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), MYGN carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 69.9%, and ROIC of -35.0%. By comparison, ACHV (Achieve Life Sciences Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $702.8M) and NNNN (Anbio Biotechnology (Class A)) posts a D- grade (35/100 RQD, P/E 83.6x, ROIC 17.0%, cap $483.5M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MYGN?

Per MYGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899923), Myriad Genetics Inc. generated $824.5M in revenue (-1.6% YoY), -$366.0M in net income, and $1.8M in free cash flow against $706.6M in total assets and $119.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MYGN trading relative to its 50-day, 200-day, and 52-week technical levels?

MYGN last traded at $5.85 (-7.87% on volume of 1,345,446 shares), positioning the stock +34.48% above its 50-day simple moving average ($4.35) and +26.90% above its 200-day simple moving average ($4.61). Across its 52-week range of $2.74 to $8.38, MYGN sits at the 55.1% percentile with a 14-day RSI of 67.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($5.12 to $6.58).

Direct Sub-Reports: MYGN RQD Cockpit MYGN 12M Forecast MYGN Earnings & Move MYGN Dividends & DRIP MYGN Insiders & 13F MYGN Whale Options MYGN Profit Sankey MYGN News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

MYGN — Myriad Genetics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Myriad Genetics Inc. (MYGN) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $5.85 (-7.87% 1D, market capitalization $607.4M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 69.9%, operating margin of -47.0%, and free cash flow yield of 0.28%.
  • Whale 13F & Options Flow (14/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 6/9, and Debt/Equity of 0.33x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Myriad Genetics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry. It carries a market capitalization of $0.6B. Per the recent news wire, the company has announced a sale of its prenatal health testing business, which the headlines describe as a $210M transaction. — for detailed product lines, customer segments, or revenue mix.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Myriad Genetics Inc. (MYGN) reported $824.5M in annual revenue (up from $837.6M in FY2024, -1.6% YoY) and -$366.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($753.2M revenue, -$263.0M net income) through FY2025, MYGN scaled operating cash flow to $1.8M and free cash flow to $1.8M, backed by $706.6M in total assets against $119.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.28% and institutional whale pillar of 14/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $2.74 – $8.38 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -47.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), MYGN carries a macro regime beta of 1.00 and gross margin of 69.9%.

  • Key Question #1: Can MYGN sustain or expand its -47.0% operating margin and -35.0% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $824.5M and free cash flow of $1.8M, how will capital allocation balance growth reinvestment against $119.9M in total debt?
  • Key Question #3: How sensitive is MYGN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MYGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Myriad Genetics Inc. (MYGN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MYGN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MYGN Bull vs. Bear Conversation Board — What's Your Call at $5.85?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MYGN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MYGN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $7.94 (+25.0%)
📌 Pinned Debate

Reported cash of $149.6M exceeds debt of $119.9M, and a prenatal testing business sale is reported to be driving share price gains.

Don't sleep on MYGN's setup in Health Care. Reported cash of $149.6M exceeds debt of $119.9M, and a prenatal testing business sale is reported to be driving share price gains.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (47/100) backs up the fundamental quality.

ArenaChamp_24 🐂 BULL

@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: In Vitro & In Vivo Diagnostic Substances. If gross margin (69.9%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $5.46 (-14.0%)
Spot @ $6.35

Operating losses persist across FY 2023–FY 2025, with an Altman Z of 0.2 and ROIC of -35%.

Fading this rally in MYGN at $6.35. Operating losses persist across FY 2023–FY 2025, with an Altman Z of 0.2 and ROIC of -35%.. With a beta of 1.0 and the stock sitting at $6.35 (52-wk range $2.74–$8.38), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%